deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT01297400

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Sponsor: Skingenix, Inc.

Conditions Burns
Interventions Investigational Drug, MW-III Silvadene® Cream 1% [Silver Sulfadiazine]
Updated 22 times since 2017 Last updated: Nov 4, 2025 Started: Mar 11, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01297400, this PHASE2 trial focuses on Burns and remains actively recruiting participants. Sponsored by Skingenix, Inc., it has been updated 22 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Feb 2024 · 9 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

22 versions recorded

  1. Dec 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

  3. Jun 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. Feb 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  5. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

▶ Show 17 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  3. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  4. May 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2022 — May 2023 [monthly]

    Recruiting PHASE2

  6. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  7. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

  9. Oct 2021 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

  10. Apr 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

  11. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE2

  12. Apr 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  13. May 2019 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE2

  14. Jun 2018 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

  15. May 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

  16. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

  17. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Skingenix, Inc.
Data source: Skingenix, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations